MGNX
Macrogenics
Stock NASDAQ – Stock Market Prices, News & Analysis
MacroGenics develops monoclonal antibodies for the treatment of cancer and autoimmune diseases.
Macrogenics
MGNX
MacroGenics develops monoclonal antibodies for the treatment of cancer and autoimmune diseases.
Price history of Macrogenics
Price history of Macrogenics
Performance & Momentum
Strategic Analysis
Macrogenics • 2026
MacroGenics positions itself in specialized biotechnology in oncology through the development of innovative monoclonal antibodies targeting cancers and autoimmune diseases. Its model relies on cutting-edge scientific innovation aimed at differentiated treatments in a sector with high unmet medical needs.
- Recognized expertise in immuno-oncology
- Portfolio of high-potential drug candidates
- Presence in a highly demanded therapeutic segment
- History of volatile and long-term declining stock performance
- Lack of recent news enhancing visibility
Despite recent positive technical momentum, the overall long-term trend remains significantly degraded, reflecting challenges in the realization of clinical developments. Investors will need to monitor the progress of trials and partnerships to validate a potential sustainable recovery.
Similar stocks to Macrogenics
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
